STOCK TITAN
  1. Home
  2. News
  3. ACAD

Acadia Pharmaceuticals Inc - ACAD STOCK NEWS

Welcome to our dedicated news page for Acadia Pharmaceuticals (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acadia Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acadia Pharmaceuticals's position in the market.

News
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
Rhea-AI Summary
Acadia Pharmaceuticals Inc. reported strong financial results for the fourth quarter and full year 2023, with total net product sales of $726.4 million, reflecting a 40% revenue growth. The company saw fourth quarter DAYBUE™ net product sales of $87.1 million and full year net product sales of $177.2 million, along with fourth quarter NUPLAZID® net product sales of $143.9 million and full year net product sales of $549.2 million. The company also highlighted advancements in its pipeline, including the initiation of Phase 3 trials for ACP-101 in Prader-Willi syndrome and ACP-204 in Alzheimer's disease psychosis. Acadia Pharmaceuticals is optimistic about its future prospects and is set to announce top-line results from the ADVANCE-2 study by the end of the first quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.92%
Tags
earnings
-
News
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (ACAD) granted inducement awards of non-qualified stock options and restricted stock units to seventeen new employees under its 2023 Inducement Plan. The awards include 111,823 stock options and 34,087 RSUs, with specific vesting schedules tied to the employees' continued service relationship. Each stock option has an exercise price of $25.18 per share, with vesting over four years, while the RSUs vest over four years as well. The awards were approved by the Compensation Committee as inducements for the new employees' employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
-
News
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (ACAD) will report Q4 and full year 2023 financial results on February 27, 2024. A conference call and webcast will be hosted to discuss financial results and operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Acadia Announces Additions to Executive Team
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (ACAD) has announced two new executive appointments. Jennifer J. Rhodes joins as Executive Vice President, Chief Legal Officer and Secretary, and Kimberly J. Manhard as Senior Vice President, Global Strategic Planning and Execution. Austin D. Kim, Executive Vice President, General Counsel, and Secretary will be leaving after a transition period. Rhodes brings over 20 years of legal and business experience in life sciences companies. Manhard has a background in clinical development, regulatory strategy, and commercial product expansion. The company's CEO expressed excitement about the contributions of the new executives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
-
News
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Acadia Pharmaceuticals Inc. announces the granting of inducement awards to new employees in the form of stock options and restricted stock units. The awards are approved by the Compensation Committee and are in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $30.66 per share and will vest over four years, while the RSUs will also vest over four years. The awards are subject to the terms and conditions of Acadia’s 2023 Inducement Plan and an applicable award agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
Rhea-AI Summary
Acadia Pharmaceuticals Inc. announces the passing of its former President, Srdjan Stankovic M.D., M.S.P.H. Serge led Acadia's Research and Development organization for more than seven years, contributing to the approval and launch of NUPLAZID® for Parkinson's disease psychosis and DAYBUE™ for Rett syndrome. His passing is mourned by friends, colleagues, and the company. Serge's significant contributions to Acadia, patients, and caregivers are remembered and honored.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
News
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, at 9:00 a.m. Pacific Time. A live webcast will be accessible on the company’s website, www.acadia.com, and an archived recording will be available for approximately one month following the presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
conferences
-
News
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) granted inducement awards consisting of non-qualified stock options and restricted stock units to eight new employees under Acadia’s 2023 Inducement Plan. Each stock option has an exercise price per share equal to $28.47 per share and will vest over four years. The RSUs will also vest over four years. The awards are subject to the terms and conditions of Acadia’s 2023 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
none
-
News
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) receives a favorable ruling from the U.S. District Court for the District of Delaware regarding its '721 formulation patent for NUPLAZID® (pimavanserin), the drug for the treatment of Parkinson's Disease Psychosis. The Court ruled in favor of Acadia on all disputed claim construction points, affirming the strength of the patent. This ruling cancels the claims construction hearing scheduled for December 19, 2023, and the case remains scheduled for trial in December 2024. Earlier in the day, the Court also granted summary judgment to Acadia, confirming validity of Acadia's '740 composition of matter patent. The formulation patent is set to expire in 2038, while the method of use patent on the 10mg tablet of NUPLAZID runs to 2037 and the NUPLAZID composition of matter patent runs to 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none
News
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has won a summary judgment in the U.S. District Court for the District of Delaware, confirming the validity of the NUPLAZID® '740 composition of matter patent. The court ruled in favor of Acadia on all grounds, concluding the litigation against MSN Laboratories Pvt. Ltd., MSN Pharmaceuticals, Inc., and other ANDA filers. The '740 patent protects NUPLAZID into 2030, with additional patents safeguarding the drug until 2037 and 2038. This outcome demonstrates Acadia’s commitment to protecting its innovations in new treatments for disorders with high unmet need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.48%
Tags
none
Stock ACAD logo
Acadia Pharmaceuticals Inc

Nasdaq:ACAD

ACAD Rankings

#1636 Ranked by Market Cap
#572 Ranked by Stock Gains
N/A Ranked by Dividends

ACAD Stock Data

2.81B
109.87M
0.49%
99.56%
6.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ACAD

acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies